Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shingrix for COVID-19 prevention in nursing home residents
NCT04523246Phase 1Completed
- Sponsor
- University of Oklahoma
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Zoster vaccine recombinant in coronavirus disease 2019 (COVID-19), influenza and pneumonia (2 arms), sponsored by University of Oklahoma. Primary endpoint: Immune cell capacity to produce type I interferon, interferon associated molecules, and proinflammatory mediators at Day 120. Started Sep 2020; status: completed.
02
Drugs
Zoster vaccine recombinant
03
Conditions
coronavirus disease 2019 (COVID-19)influenzapneumonia
Beyond the preview
Go deeper on NCT04523246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04523246.